5 Types of Peptides Explained for Beginners (Start Here)

Most people discover peptides the same way: someone on social media is claiming one of them changed their body, and suddenly there are dozens of options all promising something different, and the question becomes where to even start.

The honest answer is that you should not start with a peptide at all. You should start with a category, and before that, you should start with a problem. That reframe is the whole point of this article.

To understand why categories matter, you need a basic map of what peptides are. A peptide is simply a short chain of amino acids, which are the same building blocks that make up proteins, and peptides function in the body as signaling molecules. They are not nutrients in the traditional sense. They do not provide raw material the way protein or fat does. Instead they send instructions to cells, telling them to do more of something or less of something. Different peptides talk to different systems, which is why organizing them by what system they talk to is the most useful starting point.

There are five categories worth knowing. Fat loss peptides, growth hormone production peptides, healing and recovery peptides, mitochondrial health peptides, and immune support peptides. The goal here is not to memorize the list. The goal is to understand what each category actually does mechanistically, so you can match the tool to the problem.

Start with growth hormone production peptides, because this is where a lot of beginners get confused. Most people assume that injecting growth hormone and using a peptide to stimulate growth hormone are the same thing. They are not. Peptides in this category work by stimulating your pituitary gland, which is the small gland at the base of your brain that controls the release of growth hormone, to produce and release more of its own growth hormone. The compound tesamorelin, which is a growth hormone releasing hormone analog, works this way. In a clinical trial in people with HIV on integrase inhibitors, tesamorelin reduced visceral fat, which is the metabolically active fat stored around the organs, by a meaningful amount over 26 weeks while preserving lean mass. The reason this matters mechanistically is that growth hormone is involved in fat metabolism, tissue repair, and cellular turnover, so a peptide that raises your own production touches all of those systems at once rather than just one.

Fat loss peptides work through a different mechanism. Some operate through something called the ghrelin receptor pathway, where ghrelin is a hormone that regulates appetite and energy storage. There is also a well established connection between growth hormone and body composition, where research going back to 1999 showed that obese individuals tend to have significantly blunted growth hormone secretion, meaning the two categories overlap more than they appear on the surface. The point is that fat loss peptides are not simply appetite suppressants. Some of them are working upstream at the hormonal level and changing how your body decides to store or burn fat.

Healing and recovery peptides operate on a completely different set of systems. These peptides tend to work on tissue regeneration, inflammation signaling, and angiogenesis, which is the process of forming new blood vessels into damaged tissue. The mechanism here is less about hormones and more about local cellular repair signals. These are often the peptides that attract people who are dealing with chronic injuries or slow recovery from training, and they represent a genuinely different category because the target is the tissue itself rather than a gland or a systemic hormone.

Mitochondrial health peptides are the category most people have not heard of yet. Your mitochondria are not just where energy is produced. They are also signaling hubs, and they release their own peptides, which researchers call mitochondrial derived peptides, or MDPs. Two of the most studied are MOTS-c and SS-31. MOTS-c, which stands for mitochondrial open reading frame of the 12S rRNA-c, is a peptide encoded in the mitochondrial genome itself and released into circulation where it regulates metabolic flexibility, which is the ability of cells to switch between fuel sources efficiently. A 2024 study found that MOTS-c attenuated immobilization induced skeletal muscle atrophy in animal models by suppressing lipid infiltration into muscle tissue, which is the process where fat essentially moves into muscle when it is not being used, degrading its quality. SS-31 works differently, by targeting cardiolipin, which is a phospholipid on the inner mitochondrial membrane that is required for the electron transport chain to function properly. When cardiolipin becomes oxidized, which happens with aging and disease, the machinery that produces ATP becomes inefficient and produces more reactive oxygen species as a byproduct. SS-31 appears to stabilize cardiolipin and improve that efficiency. Research has looked at it in both diabetic models and Alzheimer's models, where mitochondrial dysfunction appears to be a common upstream driver.

Immune support peptides round out the five categories, and the most studied here is something called Thymosin Alpha-1, which is a peptide originally isolated from thymic tissue and plays a role in regulating T cell development and immune response. Research published in 2025 shows that Thymosin Alpha-1 levels decline with age in parallel with the age related shrinkage of the thymus gland, which is the organ that trains immune cells. The peptide has been looked at in clinical contexts involving chronic infections and immune deficiency states, and its mechanism involves modulating something called regulatory T cells, which are the cells that keep immune responses calibrated so they are strong enough to respond to threats but do not overreact against the body's own tissue.

Now here is where this all becomes practical. The five categories exist because five different problems exist. Slow recovery from injury is not the same problem as visceral fat accumulation, and visceral fat accumulation is not the same problem as declining immune function after sixty, and none of those are the same as mitochondrial inefficiency contributing to fatigue and cognitive decline. Using a peptide without identifying which problem you are solving is the same as opening a toolbox and grabbing something because it looks useful.

The better sequence is: identify the system that is underperforming, understand which category of peptide speaks to that system, and then within that category look at the specific compounds, their mechanisms, the actual human data behind them, and what the known risks are. Most peptides that people read about online have a range of evidence quality behind them, some with human trials and some with only animal data, and treating both as equivalent is where people get into trouble.

The body is not a single system. It is a set of systems that communicate with each other, and peptides are signaling molecules that insert messages into those conversations. Knowing which conversation you are trying to influence is the only way to use them intelligently.

---

References

1. Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochim Biophys Acta Gen Subj. 2021. Source
2. Kumagai H, Kim SJ, Miller B et al.. Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. Am J Physiol Endocrinol Metab. 2024. Source
3. Yi X, Hu G, Yang Y et al.. Role of MOTS-c in the regulation of bone metabolism. Front Physiol. 2023. Source
4. Schwemmlein J, Maack C, Bertero E. Mitochondria as Therapeutic Targets in Heart Failure. Curr Heart Fail Rep. 2022. Source
5. Radovic M, Gartzke LP, Wink SE et al.. Targeting the Electron Transport System for Enhanced Longevity. Biomolecules. 2025. Source
6. Ding XW, Robinson M, Li R et al.. Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease. Pharmacol Res. 2021. Source
7. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001. Source
8. Simonova MA, Ivanov I, Shoshina NS et al.. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025. Source
9. Pierluigi B, D'Angelo C, Fallarino F et al.. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010. Source
10. Tokudome T, Otani K, Miyazato M et al.. Ghrelin and the heart. Peptides. 2019. Source
11. Russo SC, Ockene MW, Arpante AK et al.. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024. Source
12. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness